Cargando…
Systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large B-cell lymphoma
AIM: To evaluate trials of systemic therapies in transplant-ineligible or -experienced, relapsed/refractory diffuse large-B cell lymphoma and the impact of patient characteristics on overall response rate (ORR). PATIENTS & METHODS: Systematically reviewed multiple databases through 22 July 2021....
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Becaris Publishing Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288944/ https://www.ncbi.nlm.nih.gov/pubmed/36417238 http://dx.doi.org/10.2217/cer-2022-0146 |
_version_ | 1785062178907226112 |
---|---|
author | Miller, Sally D Lozano-Ortega, Greta Mutebi, Alex Briggs, Owanate Sail, Kavita Elliott, Brian Kalsekar, Anupama |
author_facet | Miller, Sally D Lozano-Ortega, Greta Mutebi, Alex Briggs, Owanate Sail, Kavita Elliott, Brian Kalsekar, Anupama |
author_sort | Miller, Sally D |
collection | PubMed |
description | AIM: To evaluate trials of systemic therapies in transplant-ineligible or -experienced, relapsed/refractory diffuse large-B cell lymphoma and the impact of patient characteristics on overall response rate (ORR). PATIENTS & METHODS: Systematically reviewed multiple databases through 22 July 2021. Analyzed variations in patient characteristics and their relationship with ORR across trials. RESULTS: Among 17 included trials, key patient characteristics varied substantially: primary refractory (0–69%), refractory to last line of therapy (LOT) (12–100%), ≥2 prior LOTs (14–100%), ≥3 prior LOTs (0–64%), IPI ≥3 (23–73%), tumor stage III/IV (50–90%) and median age (56–74 years). ORRs varied substantially (25–83%), correlating with these characteristics. CONCLUSION: Differences in patient characteristics significantly contribute to the variability in ORR across these trials and should be considered when contextualizing efficacy data. |
format | Online Article Text |
id | pubmed-10288944 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Becaris Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-102889442023-08-11 Systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large B-cell lymphoma Miller, Sally D Lozano-Ortega, Greta Mutebi, Alex Briggs, Owanate Sail, Kavita Elliott, Brian Kalsekar, Anupama J Comp Eff Res Systematic Review AIM: To evaluate trials of systemic therapies in transplant-ineligible or -experienced, relapsed/refractory diffuse large-B cell lymphoma and the impact of patient characteristics on overall response rate (ORR). PATIENTS & METHODS: Systematically reviewed multiple databases through 22 July 2021. Analyzed variations in patient characteristics and their relationship with ORR across trials. RESULTS: Among 17 included trials, key patient characteristics varied substantially: primary refractory (0–69%), refractory to last line of therapy (LOT) (12–100%), ≥2 prior LOTs (14–100%), ≥3 prior LOTs (0–64%), IPI ≥3 (23–73%), tumor stage III/IV (50–90%) and median age (56–74 years). ORRs varied substantially (25–83%), correlating with these characteristics. CONCLUSION: Differences in patient characteristics significantly contribute to the variability in ORR across these trials and should be considered when contextualizing efficacy data. Becaris Publishing Ltd 2022-11-23 /pmc/articles/PMC10288944/ /pubmed/36417238 http://dx.doi.org/10.2217/cer-2022-0146 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License (https://creativecommons.org/licenses/by-nc-nd/4.0/) |
spellingShingle | Systematic Review Miller, Sally D Lozano-Ortega, Greta Mutebi, Alex Briggs, Owanate Sail, Kavita Elliott, Brian Kalsekar, Anupama Systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large B-cell lymphoma |
title | Systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large B-cell lymphoma |
title_full | Systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large B-cell lymphoma |
title_fullStr | Systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large B-cell lymphoma |
title_full_unstemmed | Systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large B-cell lymphoma |
title_short | Systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large B-cell lymphoma |
title_sort | systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large b-cell lymphoma |
topic | Systematic Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288944/ https://www.ncbi.nlm.nih.gov/pubmed/36417238 http://dx.doi.org/10.2217/cer-2022-0146 |
work_keys_str_mv | AT millersallyd systematicreviewofoutcomesandpatientheterogeneityinrelapsedorrefractorydiffuselargebcelllymphoma AT lozanoortegagreta systematicreviewofoutcomesandpatientheterogeneityinrelapsedorrefractorydiffuselargebcelllymphoma AT mutebialex systematicreviewofoutcomesandpatientheterogeneityinrelapsedorrefractorydiffuselargebcelllymphoma AT briggsowanate systematicreviewofoutcomesandpatientheterogeneityinrelapsedorrefractorydiffuselargebcelllymphoma AT sailkavita systematicreviewofoutcomesandpatientheterogeneityinrelapsedorrefractorydiffuselargebcelllymphoma AT elliottbrian systematicreviewofoutcomesandpatientheterogeneityinrelapsedorrefractorydiffuselargebcelllymphoma AT kalsekaranupama systematicreviewofoutcomesandpatientheterogeneityinrelapsedorrefractorydiffuselargebcelllymphoma |